QCI INTERPRET FOR ONCOLOGY
QCI Interpret for Oncology
Going beyond: Molecular evidence for off-label therapy use
Kathryn Bungartz, Ph.D., Associate StaffField Application Scientist, QIAGEN Digital...
QCI Interpret for Oncology
Expert insights to advance NGS oncology profiling
Recently, GenomeWeb and Qiagen partnered on a survey that allowed participants to...
QCI Interpret for Oncology
QCI Interpret One: Oncology variant interpretation just got more precise
Competing to offer a comprehensive genomic profiling service for solid or hematology...
QCI Interpret for Oncology
Reduce your test turnaround for large cancer panels
Speaker: Sheryl Elkin, CSO, QDI, QIAGEN Interested in learning more? Click here
QCI Interpret for Oncology
Managing multiple biomarker therapeutic development
For the past two decades, the paradigm in the field has been “one biomarker, one drug,”...
QCI Interpret for Oncology
Precision medicine for any cancer assay on any platform
For NGS cancer testing, keeping pace with new discoveries is a serious bottleneck....